New Zealand · Delayed Price · Currency is NZD AFT Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Sales grew 33% year-over-year to nearly NZD 115 million, with strong gains in Australia, Asia, and international markets. Operating profit rebounded to NZD 4.7 million, and guidance for EBIT and revenue was maintained despite higher R&D and ERP costs.
Fiscal Year 2025
-
The meeting highlighted record revenue, robust Australasian performance, and ambitious global expansion plans. An increased dividend was announced, and the board emphasized ongoing R&D investment and governance. Shareholders approved all resolutions, including director appointments.
-
Sales reached NZD 208 million, with strong growth in Australia and New Zealand and ongoing global expansion. Operating profit was impacted by lower licensing income and continued investment, but net debt and dividends improved. FY 2026 EBIT guidance is NZD 20–24 million.
-
First-half FY25 revenue grew 4% to NZD 86.7 million, with strong gains in Australia and New Zealand offset by one-off events in Asia and international markets. A strong second-half recovery is expected, with full-year EBITDA guidance of NZD 15–20 million and a sales target of NZD 300 million by FY27.
Fiscal Year 2024
-
The meeting highlighted strong revenue and profit growth, global expansion, and a robust product pipeline, with a focus on long-term R&D investment and sustainability. Shareholders approved all resolutions and discussed share price concerns, governance, and future strategic plans.